Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Choi O, Krol Y, Gottlieb AB. Ogdie A, et al. Among authors: gottlieb ab. BMC Rheumatol. 2024 May 21;8(1):20. doi: 10.1186/s41927-024-00386-7. BMC Rheumatol. 2024. PMID: 38773563 Free PMC article.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group. Mease PJ, et al. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679. N Engl J Med. 2015. PMID: 26422723 Free article. Clinical Trial.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A, Blauvelt A, Lebwohl M, Feely M, Kronbergs A, Eberhart N, Zhu D, Inman E, Grace E, Holzkaemper T, Rahman P, Marzo-Ortega H, Papp KA, Merola JF, Gottlieb AB, Schwartzman S. Deodhar A, et al. Among authors: gottlieb ab. Arthritis Res Ther. 2024 Feb 12;26(1):49. doi: 10.1186/s13075-023-03257-7. Arthritis Res Ther. 2024. PMID: 38347650 Free PMC article.
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
Coates LC, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Orbai AM, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Merola JF. Coates LC, et al. Among authors: gottlieb ab. RMD Open. 2024 Feb 22;10(1):e003855. doi: 10.1136/rmdopen-2023-003855. RMD Open. 2024. PMID: 38388171 Free PMC article. Clinical Trial.
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies.
McInnes IB, Mease PJ, Tanaka Y, Gossec L, Husni ME, Kristensen LE, Warren RB, Ink B, Bajracharya R, Coarse J, Gottlieb AB. McInnes IB, et al. Among authors: gottlieb ab. ACR Open Rheumatol. 2024 Nov;6(11):720-731. doi: 10.1002/acr2.11727. Epub 2024 Jul 30. ACR Open Rheumatol. 2024. PMID: 39077886 Free PMC article.
Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation's 2019 Annual Survey.
Zundell MP, Ogdie-Beatty AR, Perez-Chada L, Hamade H, Gondo GC, Khan AT, Bell SJ, Levy Z, Merola JF, Gottlieb AB. Zundell MP, et al. Among authors: gottlieb ab. JID Innov. 2024 Jun 6;4(5):100292. doi: 10.1016/j.xjidi.2024.100292. eCollection 2024 Sep. JID Innov. 2024. PMID: 39149524 Free PMC article.
Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies.
Schwartzman S, Puig L, Cohen AD, Khattri S, Jossart C, Diaz C, Garrelts A, Ngantcha M, Eberhart N, Eleftheriadi A, Tangsirisap N, Schuster C, Gottlieb AB. Schwartzman S, et al. Among authors: gottlieb ab. Expert Opin Drug Saf. 2024 Oct;23(10):1347-1357. doi: 10.1080/14740338.2024.2399092. Epub 2024 Sep 12. Expert Opin Drug Saf. 2024. PMID: 39234767
478 results